Applicants: Maureen J. Charron and Ellen B. Katz

Serial No.: 09/886,954 Filed: June 21, 2001

Page 2

Amendments to the Claims:

Please cancel Claim 1 without disclaimer or prejudice to applicants' right to pursue the subject matter of this claim in a future continuation or divisional application. Please amend Claims 6 and 8 as indicated below.

1.-5. (Canceled)

6. (Currently amended) The method of Claim 1,

A method for determining whether a subject has a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal is diagnostic of a defect in cell proliferation, wherein the defect in cell proliferation is a mammary adenocarcinoma or an endometrial adenocarcinoma, wherein GLUTx protein has the amino acid sequence set forth in SEQ ID NO:1, and wherein the diagnostic sample is assayed using an antibody that specifically binds to reactive with GLUTx protein.

- 7. (Original) The method of Claim 6, wherein the antibody is labeled with a detectable marker.
 - 8. (Currently amended) The method of Claim 1,

A method for determining whether a subject has a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal is diagnostic of a defect in cell proliferation, wherein the defect in cell proliferation is a mammary adenocarcinoma or an endometrial adenocarcinoma, wherein GLUTx protein has the amino acid sequence

Applicants: Maureen J. Charron and Ellen B. Katz

Serial No.: 09/886,954 Filed: June 21, 2001

Page 3

set forth in SEQ ID NO:1, and wherein the diagnostic sample is assayed using at least one nucleic acid probe that specifically which hybridizes to nucleic acid encoding GLUTx.

- 9. (Original) The method of Claim 8, wherein the nucleic acid probe is DNA or RNA.
- 10. (Original) The method of Claim 9, wherein the nucleic acid probe is labeled with a detectable marker.
- 11. (Previously presented) A method for assessing the efficacy of therapy to treat a defect in cell proliferation in a subject who has undergone or is undergoing treatment for a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal in the diagnostic sample is indicative of a need to continue therapy to treat the defect in cell proliferation, and normal GLUTx expression in the diagnostic sample is indicative of successful therapy, wherein the defect in cell proliferation is a mammary adenocarcinoma or an endometrial adenocarcinoma, and wherein GLUTx protein has the amino acid sequence set forth in SEQ ID NO:1.

12.-15. (Canceled)

- 16. (Previously presented) The method of Claim 11, wherein the diagnostic sample is assayed using an antibody reactive with GLUTx protein.
- 17. (Original) The method of Claim 16, wherein the antibody is labeled with a detectable marker.

Applicants: Maureen J. Charron and Ellen B. Katz

Serial No.: 09/886,954 Filed: June 21, 2001

Page 4

18. (Original) The method of Claim 11, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx.

- 19. (Original) The method of Claim 18, wherein the nucleic acid probe is DNA or RNA.
- 20. (Original) The method of Claim 19, wherein the nucleic acid probe is labeled with a detectable marker.

21.-35. (Canceled)